Protocol Ledger

NCT05274269 · Phase III · COMPLETED

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Interventional Phase III clinical trial protocol NCT05274269 sponsored by Vertex Pharmaceuticals in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-09 Enrollment: 307 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05274269
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)307 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05274269
Protocol FieldVerified Registry Value
NCT IdentifierNCT05274269
Consolidated Lead SponsorVertex Pharmaceuticals
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment307 participants (ACTUAL)
Registered Start Date2022-05-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05274269
Hospital Research SiteLocationSite Profile
Universitair Ziekenhuis GentGhent, BelgiumOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI